Valuation: Erasca, Inc.

Market Cap 4.68B 4.16B 3.86B 3.51B 6.62B 444B 6.73B 46.38B 18.18B 232B 17.58B 17.2B 739B P/E 2026 *
-13.5x
P/E 2027 * -20.4x
Enterprise Value 3.83B 3.41B 3.16B 2.87B 5.42B 364B 5.51B 37.98B 14.89B 190B 14.39B 14.09B 605B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.04%
Yield 2026 *
-
Yield 2027 * -
1 day-9.95%
1 week-16.47%
Current month-8.66%
1 month-9.34%
3 months-30.15%
6 months-29.56%
Current year+259.95%
1 week 13.26
Extreme 13.265
15.58
1 month 13.26
Extreme 13.265
16.2
Current year 3.36
Extreme 3.36
24.28
1 year 2.1
Extreme 2.105
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.28
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer 66 10/08/2026
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/06/26 Free

Director

29,888 0.0096%
01/04/26 Exercice

General Counsel

240,000 0.0772%
Change 5-day change 1-year change 3-year change Capi.($)
-9.95%-16.47%+453.31%+472.22% 4.68B
-6.60%-8.56%+49.38%+64.90% 65B
+0.03%+5.56%+9.10%+75.22% 51.2B
-4.09%-0.11%+2.22%+55.67% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+6.53%+8.02%+16.40%+56.32% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-1.07%+2.33%+19.43%+20.40% 22.5B
Average -2.49%-1.96%+86.30%+139.15% 37.71B
Weighted average by Cap. -2.29%-0.70%+49.33%+108.23%

Financials

2026 *2027 *
Net sales - -
Net income -322M -286M -265M -241M -455M -30.54B -462M -3.19B -1.25B -15.94B -1.21B -1.18B -50.8B -228M -203M -188M -171M -323M -21.66B -328M -2.26B -886M -11.3B -856M -838M -36.03B
Net Debt -849M -754M -699M -636M -1.2B -80.54B -1.22B -8.4B -3.29B -42.03B -3.18B -3.12B -134B -762M -677M -628M -571M -1.08B -72.29B -1.09B -7.54B -2.96B -37.73B -2.86B -2.8B -120B
Projected Income Statement - Annual - Erasca, Inc.
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
16/10/26 $13.39 -9.95% 7,089,287
15/10/26 $14.87 +1.16% 8,481,041
14/10/26 $14.70 -0.54% 4,747,560
13/10/26 $14.78 -4.40% 5,313,582
12/10/26 $15.46 -3.56% 4,280,360
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Erasca, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
13.39USD
Average target price
24.11USD
Spread / Average Target
+80.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Erasca, Inc.
  1. Stock Market
  2. Stocks
  3. ERAS Stock